Related Experiment Video

Updated: Apr 15, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.9K

Kallikrein-related peptidases targeted therapies in prostate cancer: perspectives and challenges

Vittore Cereda1, Vincenzo Formica, Antonello Menghi

  • 11 University of Rome Tor Vergata, Tor Vergata University Clinical Center, Department of Systems Medicine, Medical Oncology , Viale Oxford 81, 00133 Rome , Italy +39 0620908190 ; +39 0620903504 ; vittore.cereda@gmail.com.

Expert Opinion on Investigational Drugs
|April 11, 2015
PubMed
Abstract

Insights

Targeting kallikrein (KLK)-related peptidases offers a promising strategy for treating metastatic castration-resistant prostate cancer. Further clinical trials are needed to confirm the benefits and optimal use of KLK-targeted therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • Metastatic castration-resistant prostate cancer (mCRPC) remains a challenge despite new treatments.
  • Kallikrein (KLK)-related peptidases are implicated in prostate cancer progression by creating an oncogenic microenvironment.

Purpose of the Study:

  • To review preclinical data and clinical studies on KLK-targeted therapies for prostate cancer.
  • To assess the current status and future directions of KLK-targeted drug development.

Main Methods:

  • Summarization of preclinical evidence on KLK involvement in prostate cancer.
  • Analysis of Phase I/II clinical trial data for KLK-targeted agents.
  • Categorization of drugs by mechanism of action (inhibitors, pro-drugs, RNAi, vaccines, antibodies).

Main Results:

  • Extensive preclinical data support the role of KLKs in prostate cancer pathobiology.
  • Various KLK-targeted agents, including inhibitors, pro-drugs, RNA interference, vaccines, and antibodies, show promise.
  • Early-phase clinical studies are evaluating the efficacy and safety of these agents.

Conclusions:

  • Targeting KLK expression or activity represents a potential therapeutic avenue for prostate cancer.
  • Future clinical trials are essential to determine the efficacy, toxicity, and optimal application of KLK-targeted drugs.
  • KLK-targeted drugs may be used as monotherapy or in combination regimens.
Keywords:
engineered inhibitorsimmunotherapykallikreinkallikrein-activated prodrugskallikrein-targeted therapyprostate cancer

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
5.1K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
662
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
619
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
782